BIOMAT Database Logo BIOMAT Database Logo

Assessment of four methodologies (microparticle enzyme immunoassay, chemiluminescent enzyme immunoassay, affinity column-mediated immunoassay, and flow injection assay-tandem mass spectrometry) for measuring tacrolimus blood concentration in Japanese liver transplant recipients. 2014

S Hashi, and S Masuda, and M Kikuchi, and M Uesugi, and I Yano, and T Omura, and A Yonezawa, and Y Fujimoto, and K Ogawa, and T Kaido, and S Uemoto, and K Matsubara
Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.

Therapeutic drug monitoring (TDM) and subsequent dosage adjustment for individual patients in the treatment with tacrolimus are required after liver transplantation to prevent rejection and over-immunosuppression, which leads to severe infection and adverse reactions including nephrotoxicity. The purpose of this study was to evaluate the analytical performance among commercially available immunoassay methods, which were microparticle enzyme immunoassay (MEIA), chemiluminescent enzyme immunoassay (CLIA), and affinity column-mediated immunoassay (ACMIA), compared with an assay using liquid chromatography-tandem mass spectrometry (LC-MS/MS). In addition, the flow injection assay (FIA-MS/MS) was also evaluated to determine whether it could be available as a new method of analysis in tacrolimus therapy. The blood tacrolimus concentrations in samples from liver transplant recipients (n = 102) were measured using MEIA, CLIA, ACMIA, and LC-MS/MS. Additional blood samples from liver transplant recipients (n = 54) were analyzed using both FIA-MS/MS and LC-MS/MS. Because the assay performance and characteristics of MEIA, CLIA, ACMIA, and FIA-MS/MS are relatively different, the measured data should be carefully considered depending on the methodology.

UI MeSH Term Description Entries
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016031 Liver Transplantation The transference of a part of or an entire liver from one human or animal to another. Grafting, Liver,Hepatic Transplantation,Liver Transplant,Transplantation, Hepatic,Transplantation, Liver,Hepatic Transplantations,Liver Grafting,Liver Transplantations,Liver Transplants,Transplant, Liver
D016559 Tacrolimus A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro. Anhydrous Tacrolimus,FK-506,FK506,FR-900506,Prograf,Prograft,Tacrolimus Anhydrous,Anhydrous, Tacrolimus,FK 506,FR 900506,FR900506,Tacrolimus, Anhydrous
D049449 Luminescence Emission of LIGHT when ELECTRONS return to the electronic ground state from an excited state and lose the energy as PHOTONS. It is sometimes called cool light in contrast to INCANDESCENCE. LUMINESCENT MEASUREMENTS take advantage of this type of light emitted from LUMINESCENT AGENTS. Luminescence, Physical,Chemiluminescence,Chemiluminescence, Physical,Physical Chemiluminescence,Physical Luminescence
D053719 Tandem Mass Spectrometry A mass spectrometry technique using two (MS/MS) or more mass analyzers. With two in tandem, the precursor ions are mass-selected by a first mass analyzer, and focused into a collision region where they are then fragmented into product ions which are then characterized by a second mass analyzer. A variety of techniques are used to separate the compounds, ionize them, and introduce them to the first mass analyzer. For example, for in GC-MS/MS, GAS CHROMATOGRAPHY-MASS SPECTROMETRY is involved in separating relatively small compounds by GAS CHROMATOGRAPHY prior to injecting them into an ionization chamber for the mass selection. Mass Spectrometry-Mass Spectrometry,Mass Spectrometry Mass Spectrometry,Mass Spectrometry, Tandem

Related Publications

S Hashi, and S Masuda, and M Kikuchi, and M Uesugi, and I Yano, and T Omura, and A Yonezawa, and Y Fujimoto, and K Ogawa, and T Kaido, and S Uemoto, and K Matsubara
Cloned enzyme donor immunoassay tacrolimus assay compared with high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in liver and renal transplant recipients.
October 2007, Therapeutic drug monitoring,
S Hashi, and S Masuda, and M Kikuchi, and M Uesugi, and I Yano, and T Omura, and A Yonezawa, and Y Fujimoto, and K Ogawa, and T Kaido, and S Uemoto, and K Matsubara
Comparison of the affinity column-mediated immunoassay and microparticle enzyme immunoassay methods as a tacrolimus concentration assay in the early period after liver transplantation.
December 2010, Transplantation proceedings,
S Hashi, and S Masuda, and M Kikuchi, and M Uesugi, and I Yano, and T Omura, and A Yonezawa, and Y Fujimoto, and K Ogawa, and T Kaido, and S Uemoto, and K Matsubara
Is the affinity column-mediated immunoassay method suitable as an alternative to the microparticle enzyme immunoassay method as a blood tacrolimus assay?
December 2008, Transplantation proceedings,
S Hashi, and S Masuda, and M Kikuchi, and M Uesugi, and I Yano, and T Omura, and A Yonezawa, and Y Fujimoto, and K Ogawa, and T Kaido, and S Uemoto, and K Matsubara
Evaluation of microparticle enzyme immunoassay against HPLC-mass spectrometry for the determination of whole-blood tacrolimus in heart- and lung-transplant recipients.
October 2000, Clinical biochemistry,
S Hashi, and S Masuda, and M Kikuchi, and M Uesugi, and I Yano, and T Omura, and A Yonezawa, and Y Fujimoto, and K Ogawa, and T Kaido, and S Uemoto, and K Matsubara
False positive blood tacrolimus concentration in microparticle enzyme immunoassay.
August 2002, Biological & pharmaceutical bulletin,
S Hashi, and S Masuda, and M Kikuchi, and M Uesugi, and I Yano, and T Omura, and A Yonezawa, and Y Fujimoto, and K Ogawa, and T Kaido, and S Uemoto, and K Matsubara
Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus.
December 1996, Transplantation proceedings,
S Hashi, and S Masuda, and M Kikuchi, and M Uesugi, and I Yano, and T Omura, and A Yonezawa, and Y Fujimoto, and K Ogawa, and T Kaido, and S Uemoto, and K Matsubara
Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods.
January 2006, Transplantation proceedings,
S Hashi, and S Masuda, and M Kikuchi, and M Uesugi, and I Yano, and T Omura, and A Yonezawa, and Y Fujimoto, and K Ogawa, and T Kaido, and S Uemoto, and K Matsubara
Comparative analysis of tacrolimus (FK506) in whole blood liver transplant recipients by PRO-TRAC enzyme-linked immunosorbent assay and microparticle enzyme immunoassay IMX methods.
December 1996, Therapeutic drug monitoring,
S Hashi, and S Masuda, and M Kikuchi, and M Uesugi, and I Yano, and T Omura, and A Yonezawa, and Y Fujimoto, and K Ogawa, and T Kaido, and S Uemoto, and K Matsubara
Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients.
September 1998, Clinical chemistry,
S Hashi, and S Masuda, and M Kikuchi, and M Uesugi, and I Yano, and T Omura, and A Yonezawa, and Y Fujimoto, and K Ogawa, and T Kaido, and S Uemoto, and K Matsubara
The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients.
January 2000, Clinical therapeutics,
Copied contents to your clipboard!